A metabolomics‐based molecular pathway analysis of how the sodium‐glucose co‐transporter‐2 inhibitor dapagliflozin may slow kidney function decline in patients with diabetes

AIM: To investigate which metabolic pathways are targeted by the sodium‐glucose co‐transporter‐2 inhibitor dapagliflozin to explore the molecular processes involved in its renal protective effects. METHODS: An unbiased mass spectrometry plasma metabolomics assay was performed on baseline and follow‐...

Descripción completa

Detalles Bibliográficos
Autores principales: Mulder, Skander, Hammarstedt, Ann, Nagaraj, Sunil B., Nair, Viji, Ju, Wenjun, Hedberg, Jonatan, Greasley, Peter J., Eriksson, Jan W., Oscarsson, Jan, Heerspink, Hiddo J. L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7317707/
https://www.ncbi.nlm.nih.gov/pubmed/32115853
http://dx.doi.org/10.1111/dom.14018

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7317707/
https://www.ncbi.nlm.nih.gov/pubmed/32115853
http://dx.doi.org/10.1111/dom.14018

Ejemplares similares